Archer Materials achieves significant biochip breakthrough

Archer Materials (ASX:AXE) has successfully reduced the size of its Biochip graphene field effect transistor (gFET) design by 97%. The size has been minimized from 10mm x 10mm to 1.5mm x 1.5mm. This advancement lowers fabrication costs and enhances the chips' readiness for foundry production. The miniaturization was executed in collaboration with Applied Nanolayers and AOI Electronics.

Archer's strategic biochip development and future outlook

Archer Materials has achieved a major milestone by miniaturizing its Biochip graphene field effect transistor (gFET) design, significantly reducing its size and fabrication costs. The new chips were fabricated by Archer's partner, Applied Nanolayers, and assembled by AOI Electronics. These chips are intended for at-home testing of chronic kidney disease, which is currently under experimentation. Archer plans to integrate the new designs with additional components of the Biochip for enhanced medical diagnostics. Through these developments, Archer continues to showcase its commitment to advancing semiconductor technology with global partnerships to support its strategy in the medical diagnostics field.

Executive insights on Archer's biochip advancements

Archer has made significant progress in reducing the cost of device fabrication. This successful miniaturization of the Biochip gFET demonstrates our ability to implement a fabless commercial model. Our partnerships with Applied Nanolayers and AOI Electronics are vital in reinforcing our semiconductor supply-chain.